Literature DB >> 21681821

Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma.

Florian R Thieringer1, Thorsten Maass, Bianca Anthon, Erik Meyer, Peter Schirmacher, Thomas Longerich, Peter R Galle, Stephan Kanzler, Andreas Teufel.   

Abstract

Matrix metalloproteinase-9 (MMP-9) plays a central role in tumor invasion and development of metastases. Expression of MMP-9 had been shown in human hepatocellular carcinomas (HCCs). However, it remained unclear whether MMP-9 could influence development of HCC. In order to address this issue, we generated transgenic mice overexpressing MMP-9 in the liver. In order to avoid embryonic lethality a Cre-lox system was utilized for conditional overexpression of MMP-9 under control of an albumin enhancer and promoter. Induction of MMP-9 overexpression in transgenic mice was achieved by i.v. injection of an adenovirus coding for the Cre recombinase. Initiation of liver carcinogenesis was achieved by injection of diethylnitrosamine (DEN) followed by Phenobarbital administration in drinking water. Transgene expression was induced at the age of 6 wk. Four and six months later mice were sacrificed and examined macroscopically and microscopically in a blinded manner. Alb/Cre/MMP-9-transgenic mice showed liver specific overexpression of MMP-9-mRNA and protein after induction. At the age of 6 months livers of transgenic mice showed 15.7 ± 11.6 tumors (mean ± SD) in contrast to wildtype mice with only 7.9 ± 11.0 tumors (P < 0.03). By histopathology examination of the livers HCCs were identified in 42% of the transgenic mouse livers but only 8% in wildtype animals. In summary, we established a novel MMP-9 transgenic mouse model, and report on a significantly increased susceptibility of MMP-9 transgenic mice to chemically induced carcinogenesis. This is the first in vivo proof that MMP-9 overexpression promotes liver tumor development.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681821     DOI: 10.1002/mc.20809

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

Review 1.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

Review 2.  The Roles of Neutrophils in the Pathogenesis of Liver Diseases.

Authors:  Jiaojiao Tang; Zijun Yan; Qiyu Feng; Lexing Yu; Hongyang Wang
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

3.  1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-β1, FSCN1, Vimentin, VEGF, and MMP-9.

Authors:  Heba M I Abdallah; Sally A El Awdan; Rehab F Abdel-Rahman; Abdel Razik H Farrag; Rasha M Allam
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

4.  microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.

Authors:  Yaqin Li; Tao Zhou; Xianyi Cheng; Dezhi Li; Meng Zhao; Wei V Zheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 5.  MMP9: A Tough Target for Targeted Therapy for Cancer.

Authors:  Katarzyna Augoff; Anita Hryniewicz-Jankowska; Renata Tabola; Kamilla Stach
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

6.  Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Authors:  Antonietta Rosella Farina; Andrew Reay Mackay
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.